T2D treatment approaches included metformin (77%), either as a single treatment (27%) or co-administered with insulin (23%), Glucagon-Like Peptide-1 (GLP-1) analogues (9%), inhibitors of Sodium-glucose cotransporter-2 (iSGLT2) (12%), or inhibitors of Dipeptidyl Peptidase IV (iDPP-IV) (6%); insulin alone 9%, and diet only 14%. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.